Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

This image opens in the lightbox

News provided by

Coherent Market Insights

08 Dec, 2023, 07:14 GMT

Share this article

Share toX

Share this article

Share toX

BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.

Market Dynamics:

The Red Biotechnology Market is driven by several factors that contribute to its growth. One of the key drivers is the increasing prevalence of chronic diseases. Chronic diseases such as cancer, diabetes, and cardiovascular diseases are major public health concerns worldwide. Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases. The advancements in genetic engineering, cell therapy, and tissue engineering have significantly contributed to the development of targeted therapies and personalized medicine, thereby driving the growth of the Red Biotechnology Market.

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6416 

Another driver of the market is the growing investment in research and development activities. Several pharmaceutical and biotechnology companies are investing heavily in R&D activities to discover and develop novel therapeutics and drugs. This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market.

Market Trends:

Increasing focus on gene therapies: Gene therapy is a promising field in red biotechnology that involves the introduction of genetic material into a patient's cells to treat or prevent genetic diseases. There has been a growing focus on developing gene therapies to tackle various inherited disorders and genetic diseases. The advancements in gene editing technologies, such as CRISPR-Cas9, have enabled the development of more targeted and efficient gene therapies, further propelling the market growth.

Rising adoption of biosimilars: Biosimilars are biological products that are highly similar to an already approved reference biologic product. They have gained significant attention in the pharmaceutical industry, as they offer cost-effective alternatives to expensive biologic drugs. The increasing demand for cost-effective treatments and the expiration of patents for several biologic drugs have led to a rise in the adoption of biosimilars. This trend is expected to continue driving the growth.

Recent development:

In September 2021, the BRD Pharmaceutical Company introduced generic Cabozantinib, which is used to treat several types of cancer.

In November 2022, TriSalus Life Science announced a final merger agreement with MedTech Acquisition Corporation.

Market Opportunities:

The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market. Biopharmaceuticals are drugs that are produced using biotechnology processes and are derived from living organisms. These drugs have gained popularity in the medical field due to their effectiveness in treating various diseases, including cancer, autoimmune disorders, and genetic disorders.

Advancements in technology have facilitated the development of more targeted and personalized biopharmaceuticals, which are expected to drive the market growth. Additionally, the rising prevalence of chronic diseases and the increasing geriatric population are factors contributing to the demand for biopharmaceuticals.

Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6416 

Growing Applications of Red Biotechnology in Drug Discovery and Development

The application of red biotechnology in drug discovery and development is anticipated to create significant opportunities in the market. Red biotechnology plays a crucial role in the pharmaceutical industry by providing tools and techniques for the development and production of new drugs.

The drug discovery and development process involves identifying potential drug targets, synthesizing and testing compounds, and conducting clinical trials. Red biotechnology offers various tools such as genomics, proteomics, and bioinformatics, which aid in the discovery and development of innovative drugs.

The increasing demand for novel therapeutics, personalized medicine, and the need to optimize drug development processes are factors driving the growth of red biotechnology in drug discovery and development.

Key Market Takeaways:

The Red Biotechnology Market is anticipated to witness a CAGR of 10.7% during the forecast period 2023-2030, owing to the increasing adoption of biopharmaceuticals and the growing applications of red biotechnology in drug discovery and development.

On the basis of product type, the biopharmaceuticals segment is expected to hold a dominant position, owing to its effectiveness in treating various diseases. The biosimilars, gene therapy, tissue engineering, and cell therapy segments also contribute to the market growth.

In terms of application, the drug discovery and development segment dominates the market, as it plays a crucial role in the pharmaceutical industry. The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

In terms of end users, the pharmaceutical and biopharmaceutical companies hold a dominant position due to their involvement in the production and distribution of biopharmaceuticals. Research institutes, biotechnology industries, hospitals and diagnostic centres, and academic institutions also contribute to the market growth.

In terms of region, North America is expected to hold a dominant position over the forecast period, due to the presence of key players and technological advancements in the region.

Key players operating in the Red Biotechnology Market include Amgen Inc., Gilead Sciences, Inc., Biogen, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Johnson & Johnson Services, Inc., Sanofi, Merck & Co. Inc., AbbVie Inc., GSK plc., AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S, Bayer AG, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, and Astellas Pharma Inc. These key players play a crucial role in driving market growth through product development, collaborations, and strategic partnerships.

Read complete market research report," Red Biotechnology Market, By Product Type, By Application, By End User, By Region, and Segment Forecast 2023-2030", Published by Coherent Market Insights.

Detailed Segmentation:

By Product Type:

    • Biopharmaceuticals
    • Biosimilars
    • Gene Therapy
    • Tissue Engineering
    • Cell Therapy

By Application:

    • Drug Discovery & Development
    • Animal Biotechnology
    • Environmental Biotechnology
    • Medical Biotechnology
    • Industrial Biotechnology
    • Agricultural Biotechnology
    • Others

By End User:

    • Pharmaceutical & Biopharmaceutical Companies
    • Research Institutes
    • Biotechnology Industry
    • Hospitals & Diagnostic Centers
    • Academic Institutions

By Region

  • North America
    - U.S.
    - Canada
  • Latin America
    - Brazil
    - Mexico
    - Rest of Latin America
  • Europe
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
  • Asia Pacific
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - Rest of Asia Pacific
  • Middle East & Africa
    - South Africa
    - GCC Countries
    - Rest of Middle East & Africa

Ask for Customization: https://www.coherentmarketinsights.com/insight/request-customization/6416 

Find more related trending reports below:

Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –

Biotechnology Market, By Application (Biopharmaceutical, Bio services, Bio-Agriculture, Research), By Technology (Fermentation, Tissue engineering, PCR technology, Nanobiotechnology, Chromatography, DNA Sequencing Technology, Cell Based Assay, Other Technologies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Procrit, Epogen), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP))), By Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), By Geography (Gulf and Egypt)

Bioprocess Validation Market, By Test Type (Extractable Testing Services, Microbiological Testing Services, Physiochemical Testing Services, Integrity Testing Services, and Others (Compatibility Testing Services and Others)), By Process Component (Filter Elements, Media containers and bags, Freezing And Thawing Process Bags, Bioreactors, Transfer Systems, and Others (Mixing Systems and Others)), By End User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations, Academic and Research Institutes, and Other (Clinical Research Organizations and Others)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone: 
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Logo - https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Modal title

Also from this source

Global Cardiovascular Health Supplements Market worth $16.06 billion by 2030, Exclusive Report by Coherent Market Insights

Global Cardiovascular Health Supplements Market worth $16.06 billion by 2030, Exclusive Report by Coherent Market Insights

The global Cardiovascular Health Supplements Market is estimated to be valued at US$ 9.85 Bn in 2023 and is expected to exhibit a CAGR of 7.2% over...

Global Glucose Biosensor Market Size to hit $21.3 billion by 2031, growing at a CAGR of 7.7%, says Coherent Market Insights

Global Glucose Biosensor Market Size to hit $21.3 billion by 2031, growing at a CAGR of 7.7%, says Coherent Market Insights

The global Glucose Biosensor Market is projected to grow from USD 11.77 billion in 2023 to USD 21.3 billion by 2031, with a compound annual growth...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.